1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats

Psychopharmacology

Volumn 232, Issue 6, 2015, Pages 1025-1038

  Popik, Piotr ^a   Holuj, Malgorzata ^a   Nikiforuk, Agnieszka ^a   Kos, Tomasz ^a   Trullas, Ramon ^b   Skolnick, Phil ^c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b CSIC   (Spain)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

1 Aminocyclopropanecarboxylic acid; ACPC; Animal models; Attention; Attentional set shifting test; Cognitive flexibility; Five choice serial reaction time task (5 CSRTT); Impulsivity; Learning; Memory; Prefrontal cortex; Schizophrenia; Strychnine insensitive glycine NMDA site

Indexed keywords

1 AMINOCYCLOPROPANECARBOXYLIC ACID; CLOZAPINE; DIZOCILPINE; KETAMINE; PHENCYCLIDINE; 1-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID; AMINO ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT;

AMNESIA; ANIMAL EXPERIMENT; ARTICLE; ATTENTION; ATTENTIONAL SET SHIFTING TEST; AVOIDANCE BEHAVIOR; COGNITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; EXPERIMENTAL COGNITIVE TEST; FIVE CHOICE SERIAL REACTION TIME TASK; HYPERACTIVITY; IMPULSIVENESS; MALE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RAT; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MEMORY; REACTION TIME;

AMINO ACIDS, CYCLIC; ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CLOZAPINE; COGNITION; KETAMINE; MALE; MEMORY; NEUROPROTECTIVE AGENTS; PHENCYCLIDINE; RATS; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84925536342     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3738-4     Document Type: Article

References (67)

1. Amitai N, Markou A (2010) Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry 68:5-16
2. Auclair AL, Kleven MS, Besnard J, Depoortere R, Newman-Tancredi A (2006) Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31:1900-1909
3. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794
4. Bannerman DM, Butcher SP, Good MA, Morris RGM (1997) Intracerebroventricular infusion of the NMDA receptor-associated glycine site antagonist 7-chlorokynurenate impairs water maze performance but fails to block hippocampal long-term potentiation in vivo. Neurobiol Learn Mem 68:252-270
5. Bari A, Dalley JW, Robbins TW (2008) The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 3:759-767
6. Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320-4324
7. Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, Pichat P, Griebel G, Weiner I (2009) Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202:385-396
8. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vige X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 91:47-58
9. Carli M, Balducci C, Samanin R (2001) Stimulation of 5-HT1A receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. Psychopharmacology 158:39-47
10. Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003:318-327
11. Danysz W, Parsons CG (1998) Glycine and NMDA receptors - physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664
12. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vige X, Biton B, Steinberg R, Francon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrie P, Scatton B (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-I SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30:1963-1985
13. D'Souza DC, Singh N, Elander J, Carbuto M, Pittman B, Udo de Haes J, Sjogren M, Peeters P, Ranganathan M, Schipper J (2012) Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 37:1036-1046
14. Duffy S, Labrie V, Roder JC (2008) D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology 33:1004-1018
15. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl) 179:77-84
16. Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31:47-59
17. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002) D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56:19-23
18. Faiman CP, Viu E, Skolnick P, Trullas R (1994) Differential effects of compounds that act at strychnine-insensitive glycine receptors in a punishment procedure. J Pharmacol Exp Ther 270:528-533
19. Fijal K, Popik P, Nikiforuk A (2014) Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats. Psychopharmacology 231:269-281
20. Fossom LH, Von Lubitz DKJE, Lin RCS, Skolnick P (1995) Neuroprotective actions of 1-aminocyclopropanecarboxylic acid (ACPC): a partial agonist at strychnine-insensitive glycine sites. Neurol Res 17:265-269
21. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154
22. Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129:79-84
23. Harvey RJ, Yee BK (2013) Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 12:866-885
24. Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367-377
25. Heresco-Levy U, Javitt DC (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89-96
26. Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, Kremer I (2013) A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 16:501-506
27. Higgins GA, Enderlin M, Haman M, Fletcher PJ (2003) The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berl) 170:309-319
28. Howell DC (1997) Statistical methods for psychology. Wadsworth, Belmont
29. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
30. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236
31. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
32. Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529
33. Karasawa JI, Hashimoto K, Chaki S (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186:78-83
34. Karcz-Kubicha M, Jessa M, Nazar M, Plaznik A, Hartmann S, Parsons CG, Danysz W (1997) Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology 36:1355-1367
35. Karcz-Kubicha M, Wedzony K, Zajaczkowski W, Danysz W (1999) NMDA receptor antagonists acting at the glycineB site in rat models for antipsychotic-like activity. J Neural Transm 106:1189-1204
36. Kingwell K (2014) Schizophrenia drug gets negative results for negative symptoms. Nat Rev Drug Discov 13:244-245
37. Kolesnikov YA, Maccecchini M-L, Pasternak GW (1994) 1-Aminocyclopropanecarboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci 55:1393-1398
38. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
39. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE (2005) Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62:1196-1204
40. Layer RT, Popik P, Nowak G, Paul IA, Trullas R, Skolnick P (1998) A unified theory of antidepressant action: evidence from adaptation of the N-methyl-D-aspartate (NMDA) receptor complex following chronic antidepressant treatments. In: Soria B, Cena V (eds) Ion channel pharmacology. Oxford University Press, London, pp 438-457
41. Lewis DA, Gonzalez-Burgos G (2008) Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33:141-165
42. Lipina T, Labrie V, Weiner I, Roder J (2005) Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) 179:54-67
43. Marvizon JC, Lewin AH, Skolnick P (1989) 1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem 52:992-994
44. Monahan JB, Handelmann GE, Hood WF, Cordi AA (1989) D-cycloserine, a positive modulator of the NMDA receptor, enhances learning and memory in rats. Pharmacol Biochem Behav 34:649-665
45. Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5:101-106
46. Nikiforuk A, Golembiowska K, Popik P (2010) Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 20:37-48
47. Nikiforuk A, Kos T, Rafa D, Behl B, Bespalov A, Popik P (2011) Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycineB/NMDA receptor-dependent manner. Neuropharmacology 61:262-267
48. Nikiforuk A, Fijal K, Potasiewicz A, Popik P, Kos T (2013) The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats. J Psychopharmacol 27:469-476
49. Papp M, Moryl E (1996) Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 316:145-151
50. Popik P, Rygielska Z (1999) A partial agonist at strychnine-insensitive glycine sites facilitates spatial learning in aged rats. J Physiol Pharmacol 50:139-151
51. Pussinen R, Sirvio J (1999) Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol 13:171-179
52. Raiteri L, Raiteri M (2010) Functional 'glial' GLYT1 glycine transporters expressed in neurons. J Neurochem 114:647-653
53. Shimazaki T, Kaku A, Chaki S (2010) D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology 209:263-270
54. Singer P, Feldon J, Yee BK (2009) The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (Berl) 202:371-384
55. Stefani MR, Groth K, Moghaddam B (2003) Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav Neurosci 117:728-737
56. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA (1998) Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 140:75-80
57. Toth E, Lajtha A (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11:393-400
58. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1-10
59. Trullas R, Jackson B, Skolnick P (1989) Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav 34:313-316
60. Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P (1991) 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 203:379-385
61. Tsai GE, Lin PY (2010) Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 16:522-537
62. Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72:225-234
63. Viu E, Zapata A, Capdevila J, Skolnick P, Trullas R (2000) Glycine(B) receptor antagonists and partial agonists prevent memory deficits in inhibitory avoidance learning. Neurobiol Learn Mem 74:146-160
64. Von Lubitz DKJE, Lin RCS, McKenzie RJ, Devlin TM, McCabe RT, Skolnick P (1992) A novel treatment of global cerebral ischaemia with a glycine partial agonist. Eur J Pharmacol 219:153-158
65. Wadenberg ML, Hicks PB (1999) The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862
66. Wadenberg ML, Young KA, Trompler RA, Zavodny RA, Richter TJ, Hicks PB (1997) A novel computer-controlled conditioned avoidance apparatus for rats. J Pharmacol Toxicol Methods 38:211-215
67. Witkin JM, Tortella FC (1991) Modulators of N-methyl-D-aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions. Life Sci 48:L51-L56